4.7 Article

Bisphosphonates for the Treatment of Calcinosis Cutis-A Retrospective Single-Center Study

Journal

BIOMEDICINES
Volume 9, Issue 11, Pages -

Publisher

MDPI
DOI: 10.3390/biomedicines9111698

Keywords

calcinosis cutis; bisphosphonates; pamidronate; autoimmune connective tissue diseases; systemic sclerosis; dermatomyositis; treatment

Ask authors/readers for more resources

Bisphosphonates show beneficial effects in a subgroup of patients with calcinosis cutis. Most patients have positive subjective evaluations, with improvement seen in approximately half of the cases. A careful risk-benefit evaluation is necessary before treatment initiation due to potential severe side effects.
(1) Background: Calcinosis cutis is a frequent symptom of autoimmune connective tissue diseases leading to pain, transcutaneous expulsion of calcified material and bacterial superinfection. There is a high need for new therapeutic options as no standardized treatment algorithm is established. While case reports indicate beneficial effects of bisphosphonates, standardized evaluation of treatment effects is missing. (2) Methods: In this retrospective analysis we evaluate the effects of intravenous pamidronate, a second-generation bisphosphonate, in seven patients with calcinosis cutis using consecutive clinical pictures, radiological examinations and patient's subjective evaluation. (3) Results: 5/6 patients reported a reduction of pain, improvement of general condition and cessation of calcinosis progression. Regression of skin lesions was detectable in clinical pictures of 2/6 patients, while 1/6 patients had stable disease. Radiological examination revealed improvement or stable disease in 3/5 patients. Fever was the most common side effect. One out of seven patients developed osteonecrosis of the jaw. (4) Conclusions: Bisphosphonates appear to have beneficial effects in a subgroup of calcinosis cutis patients. While patient's subjective evaluation was mainly positive, objective assessments showed improvement in approximately half of the cases. With regard to potential severe side effects, a careful risk-benefit evaluation is necessary before treatment initiation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available